Rimag Partners with Qingyang Government on AI Medical Imaging Infrastructure
CompanyDeals

Rimag Partners with Qingyang Government on AI Medical Imaging Infrastructure

Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides
CompanyDeals

Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides

CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication
CompanyDrug

CStone’s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication

Salubris' SAL0139 Wins NMPA Nod for Hyperlipidemia Clinical Trial
CompanyDrug

Salubris’ SAL0139 Wins NMPA Nod for Hyperlipidemia Clinical Trial

Zhongsheng's Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient
CompanyDrug

Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient

HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options
CompanyDeals

HBM and AstraZeneca Deepen ADC/TCE Collaboration as AstraZeneca Exercises License Options

Kelun-Biotech's Sac-TMT Achieves First ADC-IO NSCLC Success
CompanyDrug

Kelun-Biotech’s Sac-TMT Achieves First ADC-IO NSCLC Success

Luye's LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer's and Parkinson's
CompanyDrug

Luye’s LY03017 Wins FDA Nod for Psychosis Trials in Alzheimer’s and Parkinson’s

CSPC's SYH2056 Wins NMPA Nod for Depression Trials as Fast‑Acting 5‑HT2A Agonist
Others

CSPC’s SYH2056 Wins NMPA Nod for Depression Trials as Fast‑Acting 5‑HT2A Agonist

Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC
CompanyDrug

Biokin’s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC

Phrontline Raises $60M Series Pre‑A+ to Advance Bispecific ADC Pipeline
CompanyDeals

Phrontline Raises $60M Series Pre‑A+ to Advance Bispecific ADC Pipeline

Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal
CompanyDeals

Valo Health Partners with Merck on $3B Parkinson’s Disease Discovery Deal